Journal
ONCOGENE
Volume 31, Issue 26, Pages 3177-3189Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2011.497
Keywords
HCT116; Bax; Bak; DKO; BH3-only; apoptosis
Funding
- National Institutes of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Ask authors/readers for more resources
The intrinsic mitochondrial apoptotic pathway acts through two core pro-apoptotic proteins Bax (Bcl2-associated X protein) and Bak (Bcl2-antagonist/killer 1). Although Bax and Bak seem to have redundant roles in apoptosis, accumulating evidence also suggests that they might not be interchangeable under certain conditions, at least in some human cell lines. Here we report the generation of Bak knockout as well as BaxBak double knockout HCT116 human colon carcinoma cells. We show that Bak is dispensable for apoptosis induced by a variety of stimuli including ABT-737 but not for fluorouracil-induced apoptosis. In addition, Bax deficiency only provides partial protection against camptothecin and cisplatin-induced apoptosis and no protection against killing by Puma or ABT-737 plus Noxa overexpression. Moreover, Bak is activated normally in response to many chemotherapeutic drugs in the presence of Bax, but remains kept in check by Mcl-1 in the absence of Bax. Our data suggest that Bax and Bak are functionally redundant, but they are counteracted by distinct anti-apoptotic Bcl-2 family proteins in different species. Oncogene (2012) 31, 3177-3189; doi:10.1038/onc.2011.497; published online 7 November 2011
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available